These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 9051244

  • 21. Renal effects of amphotericin B lipid complex.
    Luke RG, Boyle JA.
    Am J Kidney Dis; 1998 May; 31(5):780-5. PubMed ID: 9590187
    [Abstract] [Full Text] [Related]

  • 22. Amphotericin B lipid complex.
    Rapp RP, Gubbins PO, Evans ME.
    Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
    [Abstract] [Full Text] [Related]

  • 23. Outcomes of invasive zygomycosis infections in renal transplant recipients.
    Forrest GN, Mankes K.
    Transpl Infect Dis; 2007 Jun; 9(2):161-4. PubMed ID: 17462005
    [Abstract] [Full Text] [Related]

  • 24. The experience is CLEAR.
    Chandrasekar P.
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
    [Abstract] [Full Text] [Related]

  • 25. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G, Luna M, Lewis RE, Chemaly R, Raad II, Kontoyiannis DP.
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [Abstract] [Full Text] [Related]

  • 26. Treatment of Candida infections with amphotericin B lipid complex.
    Ito JI, Hooshmand-Rad R.
    Clin Infect Dis; 2005 May 01; 40 Suppl 6():S384-91. PubMed ID: 15809924
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
    Winston DJ, Schiller GJ.
    Clin Infect Dis; 2000 Jan 01; 30(1):236-7. PubMed ID: 10619780
    [No Abstract] [Full Text] [Related]

  • 31. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry.
    Pappas PG.
    Clin Infect Dis; 2005 May 01; 40 Suppl 6():S379-83. PubMed ID: 15809923
    [No Abstract] [Full Text] [Related]

  • 32. Mortality rates in comparative trials of formulations of amphotericin B.
    Frothingham R.
    Clin Infect Dis; 2001 Aug 15; 33(4):582-3. PubMed ID: 11462201
    [No Abstract] [Full Text] [Related]

  • 33. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS.
    N Engl J Med; 1999 Mar 11; 340(10):764-71. PubMed ID: 10072411
    [Abstract] [Full Text] [Related]

  • 34. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients.
    Herbrecht R, Auvrignon A, Andrès E, Guillemain R, Suc A, Eyer D, Pailler C, Letscher-Bru V, Leverger G, Schaison G.
    Eur J Clin Microbiol Infect Dis; 2001 Feb 11; 20(2):77-82. PubMed ID: 11305476
    [Abstract] [Full Text] [Related]

  • 35. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM, Solé A, de la Torre M, Pastor A, Fernandez R, Saura A, Delgado M, Monte E, Gonzalez D.
    Transplant Proc; 2008 Nov 11; 40(9):3090-3. PubMed ID: 19010204
    [Abstract] [Full Text] [Related]

  • 36. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, Prados D, Clotet B, Sust M, López-Vélez R, Alvar J, Spanish HIV-Leishmania Study Group.
    J Antimicrob Chemother; 2003 Sep 11; 52(3):464-8. PubMed ID: 12888588
    [Abstract] [Full Text] [Related]

  • 37. Severe and common side-effects of amphotericin B lipid complex (Abelcet).
    Ringdén O, Jønsson V, Hansen M, Tollemar J, Jacobsen N.
    Bone Marrow Transplant; 1998 Oct 11; 22(7):733-4. PubMed ID: 9818706
    [No Abstract] [Full Text] [Related]

  • 38. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z, Diener RM, Lipman JM.
    Int J Toxicol; 2006 Oct 11; 25(4):285-94. PubMed ID: 16815817
    [Abstract] [Full Text] [Related]

  • 39. Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient.
    Crompton JA, Alexander D, Somerville T, Shihab FS.
    Transpl Infect Dis; 2004 Dec 11; 6(4):183-7. PubMed ID: 15762937
    [Abstract] [Full Text] [Related]

  • 40. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
    Barcia JP.
    Pharmacotherapy; 1998 Dec 11; 18(4):874-6. PubMed ID: 9692667
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.